Insulet Corporation research snapshot
PODD AI stock analysis reads Insulet Corporation as a high-quality diabetes device growth story that is now in a real stress test. The reference quote was $165.35 at the July 31, 2026 close, market capitalization was about $11.45 billion, and the AI score is 65 out of 100. The business still grows revenue above 30%, but two voluntary medical device corrections in 2026, an FDA-recalled lot, a securities class action, and a UBS downgrade to Neutral now dominate the debate. This page is informational research and not investment advice.
Current price
$165.35
Market cap
$11.45 billion
AI score
65 / 100
Rating
Quality growth with elevated device-safety and litigation risk
Trend status
Rebounding from the June low but still below the long-term average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Insulet sells the Omnipod tubeless insulin delivery platform, where recurring pod consumption and a growing diabetes installed base drive revenue. Growth stayed above 30% even with 2026 corrections. | High |
| Moat | The moat comes from tubeless design, switching friction, payer access, clinical familiarity, CGM integration, and manufacturing know-how, but the 2026 corrections show quality execution is part of it. | Medium |
| Management | Management raised 2026 guidance after a strong Q1 and keeps investing in next-generation Omnipod products, yet two voluntary corrections and a CFO transition raise execution questions. | Medium |
| Financial trend | Q1 2026 revenue rose 33.9% to $761.7 million with $1.30 diluted EPS, but device correction costs clipped reported margin and net income stays lumpy year to year. | High |
| Valuation | At about 38.6 times trailing EPS and 24.7 times forward EPS, PODD trades far below its 2025 multiples after the drawdown but still needs durable high growth. | Medium |
| Technical trend | Price rebounded above the 50-day moving average near $155 but remains roughly 29% below the 200-day moving average near $232. | Medium |
| Risk level | Risk is elevated from two voluntary corrections in 2026, an FDA-recalled lot, a pending class action, and dependence on one product platform. | Medium-high |
| AI confidence | High for reported financials, medium for technical levels, and lower for forward multiple and litigation assumptions. | High data confidence |
| Investment certainty | Medium for business quality, lower for near-term returns while device safety and legal outcomes are unresolved. | Medium-low |
PODD AI stock forecast
The PODD AI stock forecast uses scenario ranges from the $165.35 reference quote and a forward EPS framework. These are conditional ranges, not guaranteed targets. Refresh them after the August 5, 2026 earnings report, any new device-safety news, or a major technical break.
$250 to $300
More likely if Omnipod 5 and next-generation products keep growing above 20%, the corrections stay contained, litigation does not disrupt the business, and the market restores a higher forward multiple toward analyst high targets.
$190 to $225
More likely if growth holds in the high teens to low twenties, the forward multiple stays near the mid-20s area, and device-safety and litigation risk stays elevated but manageable.
$125 to $150
More likely if new corrections or recalls hurt trust, reimbursement slows adoption, Tandem or Medtronic regain share, or litigation and multiple compression push PODD back toward its 52-week low.
PODD AI technical analysis
PODD AI technical analysis uses the July 31, 2026 close and provider-published moving averages. Price has rebuilt a short-term recovery from the June low, but it still sits well below the 200-day moving average, so the longer trend is not repaired.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $165.35 | StockAnalysis.com reported the July 31, 2026 close at $165.35; confirm with live quotes before trading. |
| Near support | $156 to $159 | This zone overlaps the 50-day moving average near $155 and recent July reaction lows. |
| Deeper support | $148 to $153 | A move below this band would weaken the recovery and raise the odds of testing the June low. |
| Major support | $138.79 | This is the June 22, 2026 intraday low and the current 52-week low; a break would reset the setup. |
| Near resistance | $172 to $174 | Late July highs sit near $172 to $173, close to the UBS and Citi price targets. |
| Next resistance | $185 to $190 | Deutsche Bank initiated coverage at $190, and this zone marks prior breakdown price structure. |
| 50-day moving average | $155.33 | The stock was above the 50-day simple moving average at the cutoff, a mild positive for the recovery. |
| 200-day moving average | $232.15 | The stock remained well below the 200-day simple moving average, so the longer-term trend still needs repair. |
| Momentum | Neutral to improving | RSI near 55 suggests a recovery in progress rather than an overextended breakout. |
| Volume | About 1.31 million shares on July 31, 2026 | Volume was near the 20-day average around 1.27 million, so the rebound still needs stronger participation. |
| Volatility | Elevated after the 2026 drawdown | The 52-week range of $138.79 to $354.88 and short interest of 6.71% of shares show position sizing matters. |
| Invalidation | Close below $148 | A decisive close below the deeper support band would challenge the recovery and invite a retest of the $138.79 low. |
PODD AI trading strategy
The PODD AI trading strategy is a rules-based research framework, not personalized advice. It pairs business quality with chart confirmation, position sizing, and explicit invalidation levels, and it should be rechecked around the August 5, 2026 earnings report.
Wait for PODD to hold above the $156 to $159 support zone and close above $174 with volume above the recent average before treating the recovery as confirmed.
A close back below $148, a new device correction, or an adverse legal update should invalidate the setup.
If PODD retests $150 to $156 without a thesis break, compare the pullback with Q2 results, device correction updates, free cash flow, and Omnipod adoption data.
Do not average down unless maximum loss, event risk, and holding period are defined before entry.
Track U.S. and international Omnipod revenue, gross margin recovery, correction and litigation disclosures, reimbursement, and share repurchase activity.
Reduce confidence if growth stays strong but margins, free cash flow, or product trust deteriorates.
Investment research summary
Customers pay Insulet for a tubeless insulin delivery platform that reduces friction versus daily injections or tubed pumps while creating recurring pod demand.
The moat is strongest where product design, patient habits, payer coverage, clinician familiarity, CGM compatibility, and manufacturing scale reinforce each other; the 2026 corrections test execution quality.
The thesis fails if device corrections keep damaging trust, the FDA or payers act against the platform, Tandem or Medtronic regain share, or investors refuse the multiple while litigation builds.
Management delivered strong Q1 growth and raised guidance, but must now show quality control, disciplined repurchases, and pipeline execution after two corrections and a CFO transition.
Automated insulin delivery is a long-duration healthcare trend, especially type 2 diabetes expansion, but the field is regulated, competitive, and safety-sensitive.
The stock is about 53% below its 52-week high, yet it still trades at a premium growth multiple. Margin of safety depends on execution and event resolution, not just a lower price.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PODD price | $165.35 close on July 31, 2026 | StockAnalysis.com / S&P Global Market Intelligence | August 1, 2026 |
| Market cap and shares | $11.45 billion market cap, 69.26 million shares outstanding | StockAnalysis.com / S&P Global Market Intelligence | August 1, 2026 |
| 52-week range | $138.79 to $354.88, down about 44.6% over 52 weeks | StockAnalysis.com / S&P Global Market Intelligence | August 1, 2026 |
| Q1 2026 revenue | $761.7 million, up 33.9% year over year | Insulet Q1 2026 results | May 6, 2026 |
| Q1 2026 EPS | $91.1 million net income, or $1.30 diluted EPS | Insulet Q1 2026 results | May 6, 2026 |
| Q1 2026 free cash flow | $89.5 million | Insulet Q1 2026 results | May 6, 2026 |
| Cash and total debt | $480.4 million cash and equivalents, $948.1 million total debt | Insulet Q1 2026 results | May 6, 2026 |
| 2026 revenue guidance | Total revenue growth of 21% to 23% constant currency, raised from 20% to 22% | Insulet Q1 2026 results | May 6, 2026 |
| Valuation | Trailing PE 38.55, forward PE 24.68, price to free cash flow 27.55 | StockAnalysis.com statistics | August 2, 2026 |
| Analyst consensus | Buy, average price target $235.54 across 25 analysts | StockAnalysis.com / S&P Global Market Intelligence | July 28, 2026 |
| Technical moving averages | 50-day SMA $155.33, 200-day SMA $232.15, RSI near 55 | StockAnalysis.com statistics | August 2, 2026 |
| Medical device corrections | Two voluntary corrections in 2026, one on March 12 for Omnipod 5 Pod lots and one on May 26 across Omnipod 5, DASH, and Eros | Bleichmar Fonti & Auld class action notice | July 24, 2026 |
This PODD AI stock analysis is an informational research tool. It is not investment advice, a recommendation, or a promise of future performance. Forecast scenarios are based on available public data as of July 31, 2026 and can be wrong if Insulet results, product safety, litigation, reimbursement, competition, valuation multiples, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
